Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2401 to 2450 of 3030 results for all

  1. Compliance with nice-approved medicines or treatments

    Clarification on demonstrating patient access to medicines and treatments recommended by NICE Technology Appraisal (TA) or Highly Specialised Technologies (HST) guidance.

  2. Combined endoscopic and laparoscopic removal of colonic polyps (HTG354)

    Evidence-based recommendations on combined endoscopic and laparoscopic removal of colonic polyps. This involves using an endoscope in the bowel plus keyhole surgery through the skin of the abdomen to remove colonic polyps.

    HealthTech guidance
    Published
    26 September 2014
    View recommendations

    Sections for HTG354

  3. Laser-assisted cerebral vascular anastomosis without temporary arterial occlusion (HTG161)

    Evidence-based recommendations on laser-assisted cerebral vascular anastomosis without temporary arterial occlusion. This involves using a special laser device to create a bypass without the need to temporarily interrupt the blood flow to the brain.

    HealthTech guidance
    Published
    27 February 2008
    View recommendations

    Sections for HTG161

  4. Fetal vesico–amniotic shunt for lower urinary tract outflow obstruction (HTG129)

    Evidence-based recommendations on fetal vesico–amniotic shunt for lower urinary tract outflow obstruction. This involves inserting a cannula through the mother's abdominal and uterine walls into the amniotic cavity and subsequently into the bladder of the fetus.

    HealthTech guidance
    Published
    13 December 2006
    View recommendations

    Sections for HTG129

  5. Hand allotransplantation (HTG254)

    Evidence-based recommendations on hand transplant surgery (allotransplantation). This involves transplanting a hand from a recently deceased donor onto the amputated stump.

    HealthTech guidance
    Published
    23 March 2011
    View recommendations

    Sections for HTG254

  6. Percutaneous closure of patent foramen ovale for the secondary prevention of recurrent paradoxical embolism in divers (HTG243)

    Evidence-based recommendations on percutaneous closure of patent foramen ovale for the secondary prevention of recurrent paradoxical embolism in divers. This involves passing a device through a large vessel in the groin up into the heart and closing/blocking the hole in the wall.

    HealthTech guidance
    Published
    15 December 2010
    View recommendations

    Sections for HTG243

  7. moorLDI2-BI: a laser doppler blood flow imager for burn wound assessment (HTG257)

    Evidence-based recommendations on moorLDI2-BI: a laser doppler blood flow imager for burn wound assessment.

    HealthTech guidance
    Last updated
    7 August 2017
    View recommendations

    Sections for HTG257

  8. Axonics sacral neuromodulation system for treating refractory overactive bladder (HTG554)

    Evidence-based recommendations on Axonics sacral neuromodulation system for treating refractory overactive bladder.

    HealthTech guidance
    Published
    3 September 2020
    View recommendations

    Sections for HTG554

  9. NICE syndication API

    Embed NICE content in your digital products and services with our syndication API.

  10. Obinutuzumab for untreated advanced follicular lymphoma (TA513)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) for untreated advanced follicular lymphoma in adults.

    Technology appraisal guidance
    Published
    21 March 2018
    View recommendations

    Sections for TA513

  11. Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1015)

    Evidence-based recommendations on teclistamab (Tecvayli) for relapsed and refractory multiple myeloma after 3 or more treatments in adults.

    Technology appraisal guidance
    Published
    13 November 2024
    View recommendations

    Sections for TA1015

  12. Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma (TA1113)

    Evidence-based recommendations on glofitamab (Columvi) plus gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma not otherwise specified in adults.

    Technology appraisal guidance
    Published
    3 December 2025
    View recommendations

    Sections for TA1113

  13. What are the causative and contributory factors underlying the persistently very low levels of reported patient satisfaction for bladder cancer?

    appeared near the bottom of the table of patient satisfaction comparisons of all cancer types in national patient experience surveys....

    Research recommendation
    Published
    9 June 2015

  14. What is the clinical effectiveness of topical treatments (antibiotics and antiseptics) compared with oral antibiotics for the treatment of infected leg ulcer?

    ulcer with antibiotics compared with standard care or placebo. However, in all but 1 study, the ulcer was either uninfected or the...

    Research recommendation
    Published
    17 March 2020

  15. What is the efficacy and safety of COVID-specific antiviral drugs in combination with other COVID-specific antiviral drugs or COVID-specific neutralising monoclonal antibodies in people who do not need supplemental oxygen and are within 7 days of symptom onset?

    hospitalisation• duration of COVID-19 related hospitalisation• all-cause hospitalisation• all-cause mortality• need for...

    Research recommendation
    Published
    9 March 2022

  16. What is the efficacy and safety of remdesivir for people who have been vaccinated against COVID-19?

    hospitalisation• duration of COVID-19 related hospitalisation• all-cause hospitalisation• all-cause mortality• need for...

    Research recommendation
    Published
    9 March 2022

  17. superDimension Navigation System to help diagnostic sampling of peripheral lung lesions (MIB194)

    NICE has developed a medtech innovation briefing (MIB) on superDimension Navigation System to help diagnostic sampling of peripheral lung lesions .

    Medtech innovation briefing
    Published
    11 October 2019

  18. Depression in adults (QS8)

    This quality standard covers the clinical assessment and management of depression in adults aged 18 and over. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    29 June 2023
    View quality statements

    Sections for QS8

  19. What is the clinical and cost effectiveness of enhanced recovery programmes for adults having major emergency surgery?

    intraoperative and postoperative stages, so recommended that components covering all 3 stages be included. They acknowledged that the...

    Research recommendation
    Published
    26 October 2020

  20. The evidence on the safety of reinforcement of a permanent stoma with a synthetic or biological mesh to prevent a parastomal hernia shows there are serious but well-recognised complications. The evidence on efficacy is limited in quantity and quality. Therefore, this procedure should not be used unless  special arrangements   are in place for clinical governance, consent, and audit or research.

    for the public is recommended. Audit and review clinical outcomes of all patients having the procedure. NICE has identified relevant...

    Research recommendation
    Published
    15 November 2019

  21. Pancreatic cancer in adults: diagnosis and management (NG85)

    This guideline covers diagnosing and managing pancreatic cancer in adults aged 18 and over. It aims to improve care by ensuring quicker and more accurate diagnosis, and by specifying the most effective treatments for people depending on how advanced their cancer is.

    NICE guideline
    Published
    7 February 2018
    View recommendations

    Sections for NG85

  22. Truncal treatment with or without concurrent tributary treatment:- What is the clinical and cost effectiveness of concurrent phlebectomies or foam sclerotherapy for varicose tributaries during truncal endothermal ablation for varicose veins compared with: - truncal endothermal ablation without concurrent phlebectomies or foam sclerotherapy? - truncal endothermal ablation with phlebectomies or foam sclerotherapy, if needed, 6–12 weeks later?

    tributary treatment ensures a single treatment episode, and the removal of all symptomatic varicosities leads to a better immediate...

    Research recommendation
    Published
    9 June 2015

  23. 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (TA1045)

    Evidence-based recommendations on 12 standard quality house dust mite sublingual lyophilisate (SQ-HDM SLIT; Acarizax) for treating allergic rhinitis and allergic asthma caused by house dust mites.

    Technology appraisal guidance
    Published
    5 March 2025
    View recommendations

    Sections for TA1045

  24. Holistic assessment in the community:- What is the clinical and cost effectiveness of a community holistic assessment and intervention for people living with high levels of multimorbidity?

    However, the studies were conducted outside the UK and were not aimed at all adults living with multimorbidity. The guideline committee...

    Research recommendation
    Published
    18 October 2016

  25. Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (TA101)

    Evidence-based recommendations on docetaxel for treating hormone-refractory metastatic prostate cancer in adults.

    Technology appraisal guidance
    Published
    28 June 2006
    View recommendations

    Sections for TA101

  26. Short-term circulatory support with left ventricular assist devices as a bridge to cardiac transplantation or recovery (HTG115)

    Evidence-based recommendations on short-term circulatory support with left ventricular assist devices (LVAD) as a bridge to heart transplantation or recovery. This involves inserting a mechanical device into the chest to help the heart pump blood around the body.

    HealthTech guidance
    Published
    28 June 2006
    View recommendations

    Sections for HTG115

  27. Endovascular stent-grafting of popliteal aneurysms (HTG259)

    Evidence-based recommendations on endovascular stent-grafting of popliteal aneurysms. This involves inserting a ‘stent-graft’ device through the femoral artery (in the groin) lining the inside of the aneurysm.

    HealthTech guidance
    Published
    27 April 2011
    View recommendations

    Sections for HTG259

  28. Minimally invasive total hip replacement (HTG236)

    Evidence-based recommendations on minimally invasive total hip replacement. This involves replacing the damaged hip joint (the top part of the upper leg bone and the socket in the hip bone that it fits into) with an artificial one.

    HealthTech guidance
    Published
    27 October 2010
    View recommendations

    Sections for HTG236

  29. Synergo for non-muscle-invasive bladder cancer (HTG601)

    Evidence-based recommendations on Synergo for non-muscle-invasive bladder cancer.

    HealthTech guidance
    Published
    30 November 2021
    View recommendations

    Sections for HTG601

  30. Bisphosphonates for treating osteoporosis. Patient decision aid on bisphosphonates for treating osteoporosis

    vertebral or hip fractures for some different baseline risks. c NICE 2019. All rights reserved. Subject to Notice of rights. Last...

  31. Secca System for faecal incontinence (MIB66)

    NICE has developed a medtech innovation briefing (MIB) on the Secca System for faecal incontinence

    Medtech innovation briefing
    Published
    24 May 2016

  32. d-Nav insulin management app for type 2 diabetes (MIB285)

    NICE has developed a medtech innovation briefing (MIB) on d-Nav insulin management app for type 2 diabetes .

    Medtech innovation briefing
    Published
    8 February 2022

  33. Axxent electronic brachytherapy system for early stage breast cancer (MIB76)

    NICE has developed a medtech innovation briefing (MIB) on Axxent electronic brachytherapy system for early stage breast cancer

    Medtech innovation briefing
    Published
    24 August 2016

  34. Digital technologies for assessing attention deficit hyperactivity disorder (ADHD) (HTG729)

    Evidence-based recommendations on digital technologies for assessing attention deficit hyperactivity disorder (ADHD).

    HealthTech guidance
    Published
    21 October 2024
    View recommendations

    Sections for HTG729

  35. Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer (HTG642)

    Evidence-based recommendations on Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer.

    HealthTech guidance
    Published
    5 October 2022
    View recommendations

    Sections for HTG642

  36. Prontosan for treating acute and chronic wounds (HTG616)

    Evidence-based recommendations on Prontosan for treating acute and chronic wounds.

    HealthTech guidance
    Published
    8 March 2022
    View recommendations

    Sections for HTG616

  37. Digital technologies for delivering multidisciplinary weight-management services: early value assessment (HTG700)

    Early value assessment (EVA) guidance on digital technologies for delivering multidisciplinary weight-management services.

    HealthTech guidance
    Last updated
    6 March 2024
    View recommendations

    Sections for HTG700

  38. TactiCath Quartz catheter for percutaneous radiofrequency ablation in atrial fibrillation (MIB60)

    NICE has developed a medtech innovation briefing (MIB) on the TactiCath Quartz catheter for percutaneous radiofrequency ablation in atrial fibrillation

    Medtech innovation briefing
    Published
    23 March 2016

  39. What components of alcohol education delivery contribute to its effectiveness for children and young people aged 11 to 18 in full-time education, and those with special educational needs and disabilities (SEND) up to the age of 25?

    schools can ensure equality of access to the curriculum and inclusion in all school activities for SEND pupils. Therefore research is...

    Research recommendation
    Published
    25 October 2019

  40. How effective and cost effective are education-based alcohol interventions targeted at children and young people aged 11 to 25 with SEND who are thought to be vulnerable to alcohol misuse?

    schools can ensure equality of access to the curriculum and inclusion in all school activities for SEND pupils. Therefore research is...

    Research recommendation
    Published
    25 October 2019

  41. How effective are education-based alcohol prevention interventions (universal or targeted) for children and young people aged 11 to 25 with SEND in full-time education?

    schools can ensure equality of access to the curriculum and inclusion in all school activities for SEND pupils. Therefore research is...

    Research recommendation
    Published
    25 October 2019

  42. How effective and cost effective are universal, education-based alcohol interventions for children and young people aged 11 to 25 with SEND?

    schools can ensure equality of access to the curriculum and inclusion in all school activities for SEND pupils. Therefore research is...

    Research recommendation
    Published
    25 October 2019

  43. Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587)

    Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for previously untreated multiple myeloma in adults.

    Technology appraisal guidance
    Published
    26 June 2019
    View recommendations

    Sections for TA587

  44. Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)

    Evidence-based recommendations on botulinum toxin type A (Botox) for preventing headaches in adults with chronic migraine.

    Technology appraisal guidance
    Published
    27 June 2012
    View recommendations

    Sections for TA260

  45. Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer (TA911)

    Evidence-based recommendations on selpercatinib (Retsevmo) for untreated RET fusion-positive advanced non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    26 July 2023
    View recommendations

    Sections for TA911

  46. National Early Warning Score systems that alert to deteriorating adult patients in hospital (MIB205)

    NICE has developed a medtech innovation briefing (MIB) on National Early Warning Score systems that alert to deteriorating adult patients in hospital .

    Medtech innovation briefing
    Published
    18 February 2020

  47. Technology appraisal committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  48. Technology appraisal committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  49. Medical technologies advisory committee members

    Read the biographies of our medical technologies advisory committee members.

  50. Selective dorsal rhizotomy:- Does selective dorsal rhizotomy followed by intensive rehabilitation performed between the ages of 3 and 9 years in children who are at Gross Motor Function Classification System (GMFCS) level II or III result in good community mobility as a young adult?

    function. The effects reported were not consistent across all studies nor sustained across all durations of follow-up...

    Research recommendation
    Published
    9 June 2015